Indian pharmaceutical exports experienced a remarkable surge of 29% in October, reaching a total of USD 28 billion projected for the fiscal year 2024, according to S.V. Veeramani, Chairman of the Pharmaceutical Exports Promotion Council (Pharmexcil). This growth marks a significant acceleration compared to the previous months, where the sector recorded a steady 5% growth rate.
The fiscal year 2023-2024 has seen India’s drug exports increase 8% year-on-year from April to October, amounting to USD 15.7 billion, compared to USD 14.5 billion during the same period in the previous year. The uptick in October indicates a robust recovery and reflects a growing demand in major markets like the United States and Europe.
In the U.S. specifically, while Indian pharmaceutical exports represent only 10% of the USD 90 billion market demand, there exists substantial potential for expansion. Veeramani emphasized that the U.S. market’s preference for Indian pharmaceuticals is due to their consistent quality and reliable supply. In the same timeframe, the U.S. market itself grew by 9.2%, further underlining the importance of Indian producers in fulfilling the gap.
Emerging markets such as the Netherlands, Brazil, and South Africa are also becoming increasingly favorable destinations for Indian pharmaceutical exports, with Brazil ranking fourth and the Netherlands second in export volumes. However, the adverse trend in exports to Russia, which has seen a 10-15% decline, poses challenges for Indian firms but is counterbalanced by growth in other regions.
The Indian government’s emphasis on Free Trade Agreements (FTAs) is another key strategy for enhancing the pharmaceutical sector. Veeramani mentioned that ongoing negotiations with countries including the U.K., Australia, and the UAE are pivotal, as they aim to eliminate both tariff and non-tariff barriers to ensure smoother trade flows.
Despite the optimistic outlook, India continues to grapple with the challenge of dependency on active pharmaceutical ingredients (APIs) sourced from China. Although the government has initiated the Production-Linked Incentive (PLI) scheme to boost domestic manufacturing, experts predict a gradual transition that may extend over several years. In FY23, India imported USD 3.18 billion worth of APIs from China, representing a marginal increase from the previous year.
Another area of concern is India’s lower research and development budgets compared to Western counterparts. Veeramani advocates for an increase in R&D investments from the current range of 5-7% to 10%, highlighting that government price controls in India lead to lower margins, thus limiting innovation and competitiveness. Small and medium enterprises are urged to allocate more resources toward R&D, which is crucial for the long-term growth of the sector.
In conclusion, while the Indian pharmaceutical industry is experiencing robust growth, the journey towards sustainability and self-reliance in APIs, along with substantial R&D investments, will be critical in maintaining this momentum. As new markets open and FTAs progress, the outlook for Indian pharmaceutical exports in the Gulf region and beyond appears promising.
Leave a Reply